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Abstract
Background: Chronic kidney disease (CKD) reduces both Klotho expression and its shedding 
into circulation, an effect that accelerates progression and cardiovascular complications. 
However, the mechanisms that regulate Klotho release by the human kidney are still unknown. 
Methods: We measured plasma Klotho across the kidney, splanchnic organs and lung in 22 
patients (71 ± 2 years, estimated glomerular filtration rate [eGFR] 60 ± 5.4 mL/min 1.73 m2) 
during elective diagnostic cardiac catheterizations. Results: Although the Klotho average re-
nal vein concentrations were remarkably higher (by ∼9%) than arterial values, the kidney re-
moved Klotho (or was at zero balance) in 7 subjects, indicating that the kidney contribution 
to systemic Klotho is not constant. Klotho fractional enrichment across the kidney was in-
versely related to plasma sodium (r = 0.43, p = 0.045) and acid uric acid levels (r = 0.38, p = 
0.084) and directly, to renal oxygen extraction (r = 0.56, p = 0.006). In multivariate analysis, 
renal oxygen extraction was the only predictor of the enrichment of Klotho across the kidney, 
suggesting the dependence of renal Klotho release on tubular hypoxia or oxidative metabo-
lism. Klotho balance was neutral across the lung. In patients with eGFR < 60 mL/min, Klotho 
was also removed by splanchnic organs (single pass fractional extraction ∼11%). Conclusions: 
The present study identifies kidney oxygen uptake as a predictor of Klotho release, and 
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splanchnic organs as a site for Klotho removal. This study provides new understanding of kid-
ney Klotho release and suggests that modulating kidney oxygen metabolism could increase 
Klotho delivery, as an option to slow disease progression and blunt organ damage.
© 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Klotho, a transmembrane 130 KDa protein, which was initially identified as an aging 
suppressor [1], is expressed in multiple tissues but is particularly high in the kidney [2–4]. In 
the human kidney, Klotho is strongly expressed both in the distal and in the proximal convo-
luted tubule, where it acts as a co-receptor for fibroblast growth factor-23 (FGF23) receptor 
[2–4]. In addition to membrane Klotho, a secreted form of Klotho protein (soluble Klotho) is 
generated from the Klotho gene through alternative splicing or proteolytic cleavage. Soluble 
Klotho (sKlotho) is directly released into the extracellular compartment to reach distant 
tissues, where it is implicated in a variety of processes, including protection of endothelial 
function, inhibition of phosphate-driven vascular calcification, inflammation, cell senescence 
and fibrosis [5–10].
Klotho is principally synthesized in the kidney and brain, but it is expressed in multiple 
organs. The tissue localization of Klotho suggests that the kidney is a major source for the 
supply of sKlotho to systemic circulation, leading to its systemic effects [11]. However, little 
information on kidney sKlotho handling is available in humans. sKlotho levels are greater in 
blood collected from suprarenal inferior vena cava as compared to lower vena cava, suggesting 
that sKlotho is released into the circulation from the human kidney [12]. Of note, circulating 
levels of sKlotho decline in various conditions associated with renal dysfunction, such as 
during ageing [13], hypertension [14] and in patients with chronic kidney disease (CKD) [15]. 
However, the kidney may also remove sKlotho from the circulation; Hu et al. [12] observed 
that an intravenous injection of 125I-labeled Klotho protein into normal rats was followed by 
fast kidney uptake and tubular secretion, indicating that the kidney actively contributes even 
to the sKlotho clearance.
To study sKlotho handling by the human kidney and other tissues, initially we measured 
plasma sKlotho across the kidney, splanchnic organs and lung in subjects undergoing 
heart catheterizations. As a second step, we studied the clinical and biochemical determi-
nants of organ sKlotho handling in the same cohort. Our data shows that the enrichment 
of sKlotho across the human kidney after a single pass is highly variable and, better than 




Twenty-two subjects scheduled for elective cardiac catheterization were eligible for 
enrolment in this protocol at the Department of Internal Medicine, University of Genoa. In 7 
(4 males, 3 females, estimated GFR [eGFR] = 58 mL/min 1.73 m2) of these subjects, data on 
FGF23 metabolism has been previously reported [14]. The clinical characteristics of subjects 
studied here are reported in Table 1. Their mean age was 71 years; 10 participants (48%) 
were male. There were 12 participants with arterial hypertension (45%), 4 (18%) with 
diabetes; 8 of them (36%) were on renin-angiotensin-aldosterone system (RAAS) blockers, 
and 6 (27%) on statin treatment. No subject received vitamin D supplements. Their median 
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eGFR was 60 mL/min per 1.73 m2 and their mean uric acid levels were moderately increased. 
The patients were studied in the post-absorptive state, that is, after a 12–14 h fast. Three sets 
of blood samples were obtained at ∼10 min intervals from the femoral artery as well as from 
the renal veins, the hepatic veins and the pulmonary artery. The right kidney was more often 
used for sampling. In 2 subjects, both sides were sampled and results averaged. Plasma was 
quickly separated from blood cells and stored at –80  ° C until assayed. Plasma sKlotho levels 
were determined using an ELISA assay (α-Klotho Assay Kit, IBL, Japan) according to the 
manufacturer’s protocol. Samples of arterial and venous blood were all run in triplicate. All 
samples from one individual were always run in the same batch (intra-assay CV = 3.5%). 
Blood pH, pO2, pCO2, glucose, lactate and creatinine were measured with an ABL800 Flex 
apparatus (Radiometer, Copenhagen, Denmark). Blood oxygen content was calculated as 
previously described [15] from haemoglobin levels, pO2 levels and oxygen saturation.
Calculations and Statistical Methods
The arterio-venous (A-V) difference of sKlotho and other substrates across the kidney, 
splanchnic organs and lung was calculated as follows: (A) – (V), where (A) and (V) are the 
concentrations of metabolites in arterial and venous plasma. Fractional extractions and frac-
tional enrichments (FEs) were calculated as 100× ([A] – [V])/[A]). In 7 subjects in whom 
FGF23 data was available, results on kidney (A-V) differences of both FGF23 and sKlotho 
were calculated on a molar basis, considering a molecular weight of 32 KDa for FGF23 and of 
70 kDa for sKlotho. Statistical analysis was performed using Wilcoxon matched-pairs signed-
ranks test to compare arterial data with venous data (Statview Statistical Package, Abacus, 
Berkeley, CA, USA). The reported p values are based on a two-tailed calculation. Linear 
regression and correlation or Spearman analysis were employed to evaluate the relation 




BMI, kg/m2 23.5 (18.8–39)
eGFR, mL/min/1.73 m2 60.1±5.4
Creatinine, mg/dL 1.3±0.1
Haemoglobin, g/dL 12.8 (7.5–16.9)
Phosphate, mg/dL 3.4±0.1
Calcium, mg/dL 8.9 (8.6–10.5)
Glucose, mg/dL 116 (68–256)
Albumin, mg/dL 3.9±0.1
Cholesterol, mg/dL 155.6±11.6
Triglycerides, mg/dL 115.3 (46–274)
Uric acid, mg/dL 6.8±0.5
Na+, mEq/L 140±0.9
K+, mEq/L 4.3 (3.4–6.1)
CKD, eGFR ≤55 mL/min/1.73 m2, yes/no 10/12
Hypertension, yes/no 12/10
Type II diabetes, yes/no 4/18
RAAS blockers, yes/no 8/14
Statins, yes/no 6/16
Data represents mean ± SEM or median (range). BMI, body mass 
index; eGFR, estimated glomerular filtration rate; CKD, chronic kidney 
disease; RAAS, renin-angiotensin-aldosterone system.
Table 1. Clinical characteristics 
of patients
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between 2 variables. A p value of < 0.05 was considered statistically significant. All data are 
expressed as mean ± SEM.
Results
Handling of sKlotho by the Kidney, Splanchnic Organs and Lung
Individual arterial and venous plasma levels of sKlotho, as well as its A-V differences and 
enrichments across the kidney, splanchnic organs and lung are reported in Table 2. In accor-
dance with the clinical setting of patients studied here, their arterial sKlotho levels were in 
the lower normal range (280 ± 25 pg/mL) [16, 17]. Although average renal vein sKlotho 
concentrations were remarkably higher (by ∼9%), than the corresponding arterial values, 
the kidney removed sKlotho (or was at zero balance) in 7 subjects, indicating that its release 
by the kidney is not a constant finding (sKlotho arterial vs. venous concentration p = 0.12). In 
4 subjects with diabetes mellitus arterial sKlotho level was not different from nondiabetic 
subjects (208 ± 79 vs. 291 ± 34 pg/mL in diabetic and nondiabetic subjects, respectively, p = 
ns). The sKlotho enrichment in the renal vein was also not different in diabetic vs. nondiabetic 
subjects (30 ± 22 vs. 25 ± 14% respectively; p = ns). In all subjects, sKlotho FE across the 
kidney was, only as a trend, directly related to eGFR (r = 0.205, p = ns), suggesting that renal 
function per se is not a major determinant of sKlotho enrichment in the renal vein. If only 
subjects with eGFR > 60 mL were taken into consideration, the association between renal 
Klotho enrichment and eGFR was also very weak (r = 0.194. p = ns). 
Although not statistically significant, sKlotho levels in the liver vein were ∼10% lower 
than the arterial ones (Table 2). 
Clinical characteristics Univariate Multivariate
(model r2 = 0.453, 
p = 0.011)
r p value t p value
Age, years 0.262 0.238
Body weight, kg 0.331 0.133
Log BMI, kg/m2 0.119 0.599
eGFR, mL/min/1.73 m2 0.172 0.445
Creatinine, mg/dL 0.255 0.252
Log O2 extraction 0.563 0.006 2.314 0.033
Log Hb, g/dL 0.127 0.583
Phosphate, mg/dL 0.057 0.808
Log calcium, mg/dL 0.294 0.197
Log glucose, mg/dL 0.365 0.113
S. Albumin, mg/dL 0.147 0.548
Cholesterol, mg/dL 0.308 0.264
Log triglycerides, mg/dL 0.347 0.204
Uric acid, mg/dL 0.376 0.084 –1.390 0.1814 ns
Log Na+, mEq/L 0.431 0.045 –1.484 0.155 ns
Log K+, mEq/L 0.155 0.490
FE, fractional enrichment; BMI, body mass index; eGFR, estimated 
glomerular filtration rate; Hb, haemoglobin; ns, not significant.
Table 3. Univariate and 
 multivariate analyses of the 
correlation between sKlotho FE 
in the renal vein and clinical 
characteristics (n = 22)
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Arterial sKlotho levels were almost identical to systemic venous (pulmonary artery) 
whole body levels (Table 2), documenting maintained zero balance of sKlotho across these 
organs systems.
Mainly due to moderate degree anaemia, arterial oxygen content was slightly reduced in 
patients studied here. Kidney fractional oxygen extraction was on the average 14 ± 2% of 
arterial content, varying from 8 to 42%. 
Determinants of sKlotho Enrichment in the Renal Vein
As a next step, we studied whether the enrichment of sKlotho by the kidney can be 
predicted by clinical findings. Table 3 summarizes the associations between individual clinical 
data and sKlotho enrichments across the kidney. At univariate analysis, sKlotho FE was 
inversely related to plasma sodium (r = 0.431, p < 0.045; Fig. 1) and, as a trend, to uric acid 
plasma levels (r = 0.376, p = 0.084; Fig. 2), but neither to plasma phosphate nor to eGFR.
In addition, sKlotho FE was strongly associated with renal oxygen fractional extraction 
both in subjects with normal renal function (n = 12; r = 0.79, p < 0.002) and in all the study 
subjects (n = 22; r = 0.563, p = 0.006; Fig. 3).
Fig. 2. Relationship between kid-
ney Klotho fractional enrichment 
and serum uric acid levels.
Fig. 1. Relationship between kid-
ney fractional enrichment of Klo-
tho and serum sodium levels. 
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No correlation was found between arterial oxygen content and sKlotho per cent en- 
richment in the renal vein (r = 0.19, p = 0.38, ns). There was also no relationship between 
kidney sKlotho enrichment and age, weight, haemoglobin, serum albumin, BUN, glucose, 
bicarbonate, triglycerides, fibrinogen and iron levels. Using the studied variables for inclusion 
into multivariate analysis, models revealed that the kidney oxygen fractional extraction was 
the only predictor of enrichment of sKlotho in the renal vein, suggesting the dependence of 
renal sKlotho systemic release on kidney oxidative metabolism. 
sKlotho Enrichment across the Kidney according to eGFR
As a next step, to evaluate how eGFR may influence sKlotho kidney enrichment, we 
studied patients separately, according to eGFR values > 60 mL/min (n = 12, mean eGFR 81 ± 
3 ml/min 1.73 m2) or < 60 mL/min (n = 10, mean eGFR 38 ± 2 mL/min 1.73 m2; Table 4). Renal 
vein sKlotho enrichment was similarly variable in subjects with different eGFR. Fractional 
oxygen extraction was similar in patients with normal and decreased eGFR (14.8 ± 1.43 vs. 
15.6 ± 2.76%, respectively, p = ns). 
In patients with lower eGFR, a removal of sKlotho by splanchnic organs was detectable 
(artery 257 ± 34 vs. liver vein 177 ± 17 pg/mL, p < 0.025, fractional extraction ∼11%). 
sKlotho and FGF23 Kidney Handling
In 7 subjects in whom the measure of FGF23 was already available [14], it was possible 
to correlate the kidney A-V differences of both FGF23 and sKlotho. In these subjects FGF23 
Fig. 3. Relationship between frac-
tional enrichment of Klotho and 











Data is presented as mean ± SEM. eGFR, estimated glomerular 
filtration rate; FE, fractional enrichment. Artery versus vein. a p < 0.05.
Table 4. Klotho FE (“minus” 
sign) or extraction (“plus” sign) 
across the kidney and splanchnic 
organs according to eGFR
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was removed by the kidney with a single pass extraction of 15 ± 2.2%. On a molar basis, the 
ratio of FGF23 to sKlotho A-V difference across the kidney (the ratio between the A-V differ-
ences cancels out the role of blood flow, and expresses the ratio of absolute exchange rates) 
was directly related to eGFR (r = 0.873, p < 0.05; Fig. 4). This ratio was close to 1 (i.e., FGF23 
kidney uptake was 1: 1 with respect sKlotho kidney release) at eGFR values of ∼90 mL/min, 
but declined to 0 when eGFR declined to 30 mL/min. This finding is in keeping with the 
unique characteristics of FGF23-Klotho signalling in the kidney and suggests a greater depen-
dency on a high eGFR of FGF23 kidney removal than sKlotho kidney release.
Discussion
Several new observations have been made in this study. First, in contrast with the current 
assumption that the kidney constantly releases sKlotho to distant organs, we observed that 
the FE of sKlotho across the human kidney is highly variable. Another new observation is that 
a decrease in renal function per se does not to modify the kidney ability to add sKlotho to the 
renal vein, as shown by similar sKlotho enrichments in subjects with different eGFR. Third, 
this study shows that, better than by changes in eGFR, kidney oxygen extraction from blood 
predicts the enrichment of sKlotho in the renal vein, suggesting that oxygen uptake is the 
major determinant of kidney sKlotho handling and release into the circulation. As a further 
point, we observe for the first time that splanchnic organs can remove sKlotho from the circu-
lation.
The kidney has the highest level of expression of Klotho, but little is known on how 
important sKlotho circulating in serum is derived from the kidney. Serum sKlotho levels in 
patients with CKD are extremely variable [16, 17]. In contrast, renal Klotho levels are uniform-
ly reduced in experimental CKD [18–20]. In their seminal study, Hu et al. [12] observed in 
7 subjects with a GFR > 50 mL/min that suprarenal inferior vena cava enrichment of sKlotho 
was > 50%, thus demonstrating an outstanding kidney feature of sKlotho metabolism. In 
patients studied here, the fractional release of sKlotho by the kidney represented on the 
average ∼9% of its arterial plasma concentration, a figure much lower than that previously 
observed from sampling from the vena cava [12]. In addition, in 7 out of 22 subjects studied 
here, the kidney A-V difference balance of sKlotho was neutral or even positive, actually indi-
cating either sKlotho removal or zero balance from blood. Accordingly, our data obtained in 
humans indicate that in the basal, post-absorptive state, the kidney can either produce or 
remove sKlotho from blood.
Fig. 4. Relationship between 
FGF23 to Klotho A-V difference 
ratio across the kidney and eGFR. 
FGF23, fibroblast growth fac-
tor-23; eGFR, estimated glomeru-
lar filtration rate.
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In this study, besides expressing a quantitative result of sKlotho enrichment across the 
kidney, we also describe the association between sKlotho kidney handling and several 
clinical/biochemical parameters. At univariate analysis, both dehydration and low kidney 
oxygen first pass extraction predicted sKlotho kidney output. The finding that high sodium 
and high uric acid plasma levels were associated with low sKlotho enrichment in the renal 
vein suggests that hydration status may be a determinant of kidney Klotho production. This 
observation is in accordance with the evidence that a low fluid intake is a risk factor for CKD 
[21, 22] and with experimental models showing that water can protect against kidney injury 
[23]. It is interesting that in mice as well as in human embryonic kidney cells, dehydration 
causes a significant decline of renal Klotho transcript levels and protein abundance [23]. 
Besides downregulating Klotho, an elevated serum osmolality can also activate various meta-
bolic processes, including vasopressin release and activation of the aldose reductase-fructo-
kinase pathway that associate with renal injury [22] and excess mortality in the elderly [24].
However, at multiple regression analysis, oxygen fractional extraction by the kidney was 
the only predictor of sKlotho kidney enrichment. To explain this association, several hy- 
potheses can be made. The first is that oxygen fractional extraction and sKlotho enrichment 
are both dependent on the amount of viable kidney tissue. However, this hypothesis can be 
likely ruled out on the ground that the association between oxygen extraction and sKlotho 
enrichment across the kidney was also observed in subjects with preserved eGFR.
Another possibility is that sKlotho release is associated with tubular function. As a matter 
of fact, the high renal oxygen demand is associated primarily with tubular oxygen consumption, 
which is necessary for solute reabsorption. In this regard, FGF23/Klotho axis acts on sodium 
reabsorption in the proximal and distal tubules [4, 25]. Therefore, changes in solute reabsorption 
in different conditions of fluid homeostasis, oxidative stress, segmental tubular dysfunction and 
disease could represent conditions underlying changes in kidney sKlotho release. 
As a possibility, we also have to consider the role of kidney hypoxia on the development 
and progression of CKD. A role for renal hypoxia as a major determinant of renal disease 
progression was first proposed by Fine and Norman [26] and this hypothesis has been 
recently supported by many animal studies [27, 28] and by studies in humans obtained in 
vivo by MRI [29]. In subjects studied here, arterial oxygen content was slightly reduced, owing 
to their reduced haemoglobin concentrations, implying a decreased oxygen delivery to 
tissues. However, we were not able to detect an association between arterial oxygen content 
or arterial haemoglobin and fractional sKlotho enrichment in the renal vein. In accordance 
with the large excess of oxygen supply to the human kidney, we observed that ∼14% of 
arterial oxygen content was removed by the kidney after a single pass, a percentage similar 
to that observed in the normal condition [30, 31]. However, the measure of cortical oxygen-
ation was not feasible in our study, so we cannot exclude that changes in oxygen supply to 
different intrarenal sites are associated with changes in Klotho release.
Finally, in our study we also show that the kidney exchange of FGF23 and sKlotho is stoi-
chiometrically related. We previously observed that in humans, the kidney removes from 
blood FGF23 [14], an effect that is seemingly accounted for by glomerular filtration and 
tubular reabsorption. As a further extension of our previous findings, we now report that 
kidney FGF23 single-pass extraction is related to sKlotho single pass enrichment (Fig. 4). On 
a molar basis, the ratio of FGF23 to Klotho to A-V difference across the kidney declines from 
1.0 at eGFR values of ∼90 mL/min, to values close to 0 when eGFR reaches ≈30 mL/min. This 
finding is in keeping with the finding about the dependency on GFR of FGF23 kidney removal, 
while ongoing sKlotho release may expresses tubular adaptation to nephron loss. 
It is commonly assumed that the sKlotho production by the kidney declines progressively 
along with the decrease in GFR. To our surprise, we observed that the sKlotho enrichment in 
the renal vein (which expresses the kidney tissue metabolic activity) was similar in patients 
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with different eGFR studied here. On the one hand, this finding may be, at least in part, the 
expression of a lower plasma flow and Klotho wash-out from the kidney in CKD. However, 
another possible explanation is that proteolytic cleavage of the extracellular domain of the 
transmembrane form may be accelerated to compensate the Klotho reduced availability. 
Even less studied than its source, the route of elimination of sKlotho is completely 
unknown. In our study, although not statistically significant, sKlotho levels in the liver vein 
were ∼10% lower than the arterial ones. This difference was statistically different in patients 
with reduced GFR. However, we cannot understand from our study whether this finding 
expresses an effect of CKD per se or if it simply represents reduced variability in Klotho 
measurement in the cohort of patients with more reduced GFR. Our results suggest that other 
organs, besides the kidney, can remove sKlotho from the circulation and are in keeping with 
the observation (12) that an intravenous injection of 125I-labeled sKlotho protein into normal 
rats is followed by its removal not only by the kidney, but also by the liver and spleen. 
The current study has several strengths, as it provides an example of in vivo sKlotho regu-
lation in humans in a clinical setting. As a matter of fact, this study includes a cohort of non-
selected patients, in which sampling of central veins was feasible. However, a potential limi-
tation of our work is that the cohort studied might represent an aged and disease-prone popu-
lation, in which sKlotho metabolism may have been influenced by the combined events occurring 
in aging and disease. In addition, hypertension and/or diabetes, which can down-regulate 
sKlotho [32], were present in 12 out of 22 patients. Moreover, our findings may represent some 
inaccuracies in the methods currently available to detect small A-V differences of Klotho. 
Results presented here express qualitative, but not quantitative, data on sKlotho exchange 
across organs, since the measure of blood flow was not feasible in our study. In addition, the 
net balance data obtained from a simple A-V measurement can result from a variety of 
different rates of uptake and release. Therefore, zero net balance does not imply that uptake 
and release are also zero, but rather that their difference is such [33]. Although unlikely, this 
means that a given organ still produces and utilizes sKlotho but at comparable rates. 
In conclusion, the present study provides the first report of sKlotho handling measured 
across the human kidney and major organ systems in humans and identifies oxygen uptake 
as predictor of kidney sKlotho release. Our data suggests that kidney sKlotho release is part 
of a homeostatic system that links kidney energy metabolism to the release of survival 
factor(s) to extrarenal tissues. Besides providing a better understanding of physiology of 
sKlotho metabolism, the data reported in this study suggests that modulating kidney oxygen 
metabolism could increase kidney sKlotho regulation and export, as an option to blunt organ 
damage and slow disease progression.
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